{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"groups":[{"description":"Patients with no evidence of leukemia or MDS post-HCT receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 14 and aldesleukin SC BID on days 14-28.\n\nAldesleukin: Given SC\n\nLaboratory Biomarker Analysis: Correlative studies\n\nWT1-Sensitized Allogeneic T-Lymphocytes: Given IV","id":"OG000","title":"Arm I (High-risk for Relapse After HCT)"},{"description":"Patients with evidence of AML (minimal residual disease or overt relapse) post-HCT receive cyclophosphamide IV and fludarabine phosphate IV daily on days -4 to -2. Patients also receive WT1-sensitized T cells IV over 45 minutes (or longer for patients who are 15-30 kg) on days 0 and 21 and aldesleukin SC BID on days 14-28.\n\nAldesleukin: Given SC\n\nCyclophosphamide: Given IV\n\nFludarabine Phosphate: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nWT1-Sensitized Allogeneic T-Lymphocytes: Given IV","id":"OG001","title":"Arm II (Relapsed After HCT)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 1 year","title":"Disease-free Survival After T Cell Therapy","type":"SECONDARY","unitOfMeasure":"Participants"}